Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.

ProKidney Corp. targets diabetic CKD with Rilparencel and expects Q2 2027 eGFR slope data for accelerated approval. Find out ...

For a rugby legend like Rocky Elsom, the roar of the crowd has been replaced by the deafening silence of legal limbo.

Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and ...

Protect your Most Important Assets: Your Personal Information. GET your 14-Day FREE TRIAL following my link with AURA at NEW!

CalciMedica ( (CALC) ) has shared an announcement.

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Acumen Pharmaceuticals (ABOS) recently dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for sabirnetug, and also shared new Alzheimer’s research findings and ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...

Platforms went live, deals were signed and execution took centre stage as ASX tech companies gathered momentum through the December ... Read More The post ASX Quarterly Tech Wrap: From promise to ...